市場調査レポート
商品コード
1439579
子宮内膜アブレーションデバイスの世界市場:洞察、競合情勢、市場予測:2030年Endometrial Ablation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
子宮内膜アブレーションデバイスの世界市場:洞察、競合情勢、市場予測:2030年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界の子宮内膜アブレーションデバイスの市場規模は、2023年に35億3,860万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に4.95%のCAGRで拡大し、2030年には47億1,950万米ドルに達すると予測されています。子宮内膜アブレーションデバイスの需要は、主に異常膣出血、多嚢胞性卵巣疾患(PCOD)、月経痛、その他の婦人科疾患の有病率の上昇によって後押しされています。さらに、子宮内膜焼灼デバイスの安全性への注目の高まりと、製品開拓における技術革新、製品の発売や承認の急増も、2024年から2030年までの予測期間における子宮内膜焼灼デバイス市場全体の成長に寄与しています。
子宮内膜アブレーションデバイス市場は、さまざまな要因によって製品需要が伸びていますが、主要な要因の1つは、月経困難症PCODなどの婦人科疾患の有病率の上昇です。
例えば、米国疾病予防管理センター(CDC)によると(2023年)、多嚢胞性卵巣症候群(PCOS)は女性不妊の最も一般的な原因の一つであると述べられています。米国では毎年平均して、生殖年齢にある女性の6%から12%がPCOSを患っていると報告されています。
異常子宮出血(AUB)は、生殖年齢の女性に最もよく見られる疾患です。AUBは生産性の低下を引き起こし、外科的介入が必要になることもあります。National Health Portal Indiaによると、初潮から閉経までの間に、AUBは女性の9~14%に影響を及ぼすとされています。同出典によると、インドでは年間17.9%の女性がAUBに罹患している可能性があります。
したがって、月経痛、異常膣出血、PCOS、PCODなどの婦人科疾患の有病率の上昇は、効果的な治療により子宮内膜切除装置の需要を増加させ、それによって予測期間中の市場全体の成長を促進するとみられています。
当レポートでは、世界の子宮内膜アブレーションデバイス市場について調査し、市場の概要とともに、製品タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。
Endometrial Ablation Devices Market By Product Type (Cryoablation Devices, Hydrothermal Ablators, Thermal Balloon Ablator, Radiofrequency Ablators Microwave Ablators, And Others), End-User (Hospitals & Clinics, Specialty Clinics, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of gynecological disorders and the growing demand for minimally invasive surgeries across the globe
The global endometrial ablation devices market was valued at USD 3,538.60 million in 2023, growing at a CAGR of 4.95% during the forecast period from 2024 to 2030 to reach USD 4,719.50 million by 2030. The demand for endometrial ablation devices is primarily being boosted by the increasing prevalence of abnormal vaginal bleeding, polycystic ovarian disease (PCOD), menorrhagia, and other gynecological disorders. Further, the increasing focus on the safety of endometrial ablation devices and innovations in product development along with surging product launches and approvals are also contributing to the overall growth of the endometrial ablation devices market during the forecast period from 2024-2030.
Endometrial Ablation Devices Market Dynamics:
The endometrial ablation devices market is witnessing a growth in product demand owing to various factors, one of the key factors being the increase in the prevalence of gynecological disorders such as menorrhagia PCOD, and others.
For instance, according to the Centers for Disease Control and Prevention (CDC) (2023), it was stated that polycystic ovarian syndrome (PCOS) is one of the most common causes of female infertility. The source reported that each year on average 6% to 12% of women of reproductive age suffer from PCOS, in the US.
Abnormal Uterine Bleeding (AUB) is the most common disorder among reproductive-aged women. AUB causes productivity loss and may necessitate surgical intervention. As per the National Health Portal India, between menarche and menopause, AUB is claimed to affect 9 to 14% of women. As per the same source, in India, nearly 17.9% of women per year may have AUB.
Thus, the increasing prevalence of gynecological disorders such as menorrhagia, abnormal vaginal bleeding, PCOS, and PCOD will increase the demand for endometrial ablation devices owing to the effective treatment and will thereby drive the overall market growth during the forecast period.
The increasing patient preference for minimally invasive surgeries is also likely to bode well for the market growth during the forecast period. Endometrial ablation offers advantages over conventional surgeries, such as short procedure time, faster recovery, high efficiency, and lower post-treatment pain. Thus, such advantages may increase the adoption of minimally invasive treatment over the other treatment options.
The increasing developments made by the key players in the ablation segment are also contributing to the market's growth. For instance, Channel Medsystems, Inc., launched Cerene Cryotherapy Device in October 2022, for the treatment of heavy menstrual bleeding (HMB). It provides a minimally invasive endometrial ablation treatment using cooling technology (Cryoablation) that reduces menstrual bleeding and dysmenorrhea, while naturally minimizing pain without requiring general anesthesia.
Therefore, the above-mentioned factors are contributing to the growth of the endometrial ablation devices market during the forecast period from 2024-2030.
However, risks associated with endometrial ablation procedures, including infection, tearing of uterine wall, hemorrhage, and others may restrict the endometrial ablation devices market growth.
The endometrial ablation devices market experienced a period of a temporary setback as lockdown restrictions were enforced as a necessary step to curb the spread of COVID-19. The demand for endometrial ablation devices was disrupted as the treatment of gynecological disorders was classified as non-urgent and priority was given to patients suffering from covid-19 infection. Moreover, disruption in the manufacturing of devices owing to a lack of raw material and manpower, and other restrictions lead to a decreased demand for endometrial ablation devices in the market. However, with the vaccine administration and with the resumption of patients in hospitals for the treatment of gynecological disorders, the demand increased significantly in the market. Henceforth, the aforementioned factors propelled the demand for endometrial ablation devices during the pandemic and are estimated to grow similarly during the forecast period.
Endometrial Ablation Devices Market Segment Analysis:
Endometrial Ablation Devices Market by Product Type (Cryoablation devices, Hydrothermal Ablators, Thermal Balloon Ablator, Radiofrequency Ablators, Microwave Ablators, and Others), End-User (Hospitals & Clinics, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the endometrial ablation devices market, the radiofrequency ablators category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the advantages offered by the category.
Radiofrequency ablation devices are used to transmit radio frequency energy and destroy the tissue lining the uterus. These devices ensure a reduced risk of infection. The radiofrequency ablators offer speedy treatment and recovery, higher efficacy as compared to other options, more convenience, and other advantages. Moreover, radiofrequency ablators are effective for the treatment of small cancers and offer a minimally invasive approach with no skin incisions and pain.
Apart from the advantages of the devices, the factors driving segment growth are the increasing prevalence of cervical cancer, menorrhagia, and other gynecologic disorders. According to the Global Cancer Observatory 2020, nearly 417,367 new cases of endometrial cancer were reported globally in 2020. The growing incidence of uterine cancer (endometrial cancer) worldwide is expected to increase the demand for endometrial ablation devices as the device is used to remove the tumor from the endometrial wall, thereby increasing the overall market growth.
Also, the increasing technological advancement is likely to bode well for market growth during the forecast period. For instance, in September 2021, Gynesonics received approval from the US FDA for their next-generation Sonata System 2.2 radiofrequency ablation of fibroid tumors. This Sonata technology platform integrates a commercial intrauterine ultrasound system with an advanced radiofrequency ablation device to provide incision-free, uterus-preserving treatment.
Hence, the advantages offered by radiofrequency ablators along with the rising approvals and launches are predicted to contribute to the increasing demand for this product type thereby driving the growth of the overall endometrial ablation devices market during the forecast period.
North America is expected to dominate the overall Endometrial Ablation Devices Market:
Among all the regions, North America is estimated to account for the largest share of the endometrial ablation devices market in the year 2023. Owing to the rising prevalence of gynecological disorders such as PCOS, rising incidences of abnormal uterine bleeding (AUB), menorrhagia, and escalating cases of cancer such as uterine cancer among women is driving the North America endometrial ablation devices market and is expected to witness positive growth.
For instance, the American Cancer Society estimated that about 66,200 new cases of uterus cancer will be diagnosed in the United States in 2023. Also, according to the Canadian Cancer Society (2023), it was estimated that approximately 8,100 Canadian women were diagnosed with uterine cancer in 2022. Further, the CDC (2023) reported that in 2019, menorrhagia affected more than 10 million American women each year, indicating one out of every five women having it.
The aforementioned sources stated that the prevalence of gynecological disorders is increasing in the North America region. Therefore, in such cases, endometrial ablation devices are used to remove the tumor or uterus lining, ultimately increasing the demand for endometrial ablation devices, thereby driving the regional market of endometrial ablation devices during the forecast period (2024-2030).
Coupled with the factors mentioned above, increasing strategic planning among the key players will also drive the market of endometrial ablation devices. For instance, in February 2021, CooperSurgical announced the acquisition of AEGEA Medical and its FDA-approved Mara Water Vapor Ablation system. The acquisition complemented CooperSurgical's growing portfolio of medical products that were focused on clinic and practice-based women's health. Mara is an in-office treatment that ablated the lining of the uterus in under two minutes for treatment of Heavy Menstrual Bleeding (HMB) in women.
Also, in October 2021, Hologic, announced acquiring of Bolder Surgical, for USD 160 million. The complementary acquisition of Bolder Surgical added to Hologic's surgical product line, which included the NovaSure® endometrial ablation system for the treatment of abnormal uterine bleeding, the MyoSure® tissue removal devices for the treatment of intrauterine fibroids and polyps, the Acessa® laparoscopic radiofrequency ablation system for the treatment of fibroids, among others. Thus, such strategic steps help to increase the demand for endometrial ablation devices, thereby driving the North America endometrial ablation devices market forward during the forecast period.
Endometrial Ablation Devices Market Key Players:
Some of the key market players operating in the endometrial ablation devices market include Medtronic, Johnson & Johnson Services, Inc., Olympus, Minerva Surgical, Inc., Hologic, Inc., CooperSurgical Inc., Richard Wolf GmbH, AngioDynamics, KARL STORZ SE & Co. KG, IDOMAN-MED, Arthrex, Inc., Channel Medsystems, Inc., Gynesonics, Boston Scientific Corporation, AEGEA Medical, and others.
Recent Developmental Activities in the Endometrial Ablation Devices Market:
In February 2023, Hologic announced the approval of NovaSure V5 global endometrial ablation device (GEA) in Canada and Europe, which is a minimally invasive device that emits precisely measure radio-frequency energy to safely remove the endometrium, to treat Abnormal Uterine Bleeding (AUB).
In December 2022, RF Medical received US Food and Drug Administration (FDA) approval for its MYGEN M-3004 generator and MYOBLATE radiofrequency ablation system. MYGEN M-3004 enables a combination of monopolar and bipolar modes to deliver radiofrequency energy, while MYOBLATE electrodes are intended for coagulation and ablation of soft tissue to treat fibroids in a minimally invasive manner.
In May 2020, Minerva Surgical announced the closing of the acquisition of Boston Scientific's Intrauterine Health franchise. The combined product line was aimed to treat Abnormal Uterine Bleeding (AUB). The new suite of minimally invasive tools combined the Minerva Endometrial Ablation System, the fastest-growing endometrial ablation product, with the Genesys HTA(TM) Endometrial Ablation System, for visualization within the uterine cavity during treatment.
Key Takeaways from the Endometrial Ablation Devices Market Report Study
Market size analysis for current endometrial ablation devices market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the endometrial ablation devices market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global endometrial ablation devices market.
Various opportunities available for the other competitor in the endometrial ablation devices market space.
What are the top-performing segments in 2023? How these segments will perform in 2030.
Which are the top-performing regions and countries in the current endometrial ablation devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for endometrial ablation devices market growth in the coming future?
Target Audience who can be benefited from this Endometrial Ablation Devices Market Report Study
Endometrial ablation devices products providers
Research organizations and consulting companies
Endometrial ablation devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in endometrial ablation devices
Various End-users who want to know more about the endometrial ablation devices market and the latest technological developments in the endometrial ablation devices market.
Frequently Asked Questions for the Endometrial Ablation Devices Market:
Endometrial ablation devices are surgical devices that are used to remove a thin layer of tissue (endometrium) that lines the uterus. The devices are used for the treatment of heavy menstrual bleeding, endometrial cancer, gynecological disorders, and others.
The global endometrial ablation devices market was valued at USD 3,538.60 million in 2023, growing at a CAGR of 4.95% during the forecast period from 2024 to 2030 to reach USD 4,719.50 million by 2030.
The demand for endometrial ablation devices is primarily being heightened by the increasing prevalence of abnormal vaginal bleeding, polycystic ovarian disease (PCOD), menorrhagia, and other gynecological disorders. In addition, the rising demand for minimally invasive surgeries and the increasing device launches and approvals are thereby contributing to the overall growth of the endometrial ablation devices market during the forecast period from 2024-2030.
Some of the key market players operating in the endometrial ablation devices market include Medtronic, Johnson & Johnson Services, Inc., Olympus, Minerva Surgical, Inc., Hologic, Inc., CooperSurgical Inc., Richard Wolf GmbH, AngioDynamics, KARL STORZ SE & Co. KG, IDOMAN-MED, Arthrex, Inc., Channel Medsystems, Inc., Gynesonics, Boston Scientific Corporation, AEGEA Medical, and others.
North America is expected to dominate the overall endometrial ablation devices market during the forecast period from 2024-2030. Factors such as the rising prevalence of gynecological disorders such as endometrial cancer, ovarian cancer, and others, as the rising burden of lifestyle diseases with strategic planning by the key market players such as acquisitions or mergers, are expected to drive the growth of the North American endometrial ablation devices market during the forecast period.